Aurobindo Pharma Ltd's Unit 7 completes USFDA PAI successfully

The United States Food and Drug Administration (US FDA) completed a Pre-Approval Inspection (PAI) at Aurobindo Pharma Ltd's Unit VII, a Formulation Manufacturing facility situated at Jedcherla Mandal, Mahaboob Nagar District, Telangana, from July 28 to August 4, 2023.

The inspection closed with zero observations and a classification of No Action Indicated (NAI).

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 841.80 as compared to the previous close of Rs. 840.30. The total number of shares traded during the day was 48419 in over 1884 trades.

The stock hit an intraday high of Rs. 855.40 and intraday low of 832.10. The net turnover during the day was Rs. 40801904.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 USFDA PreApprovalInspection Unit7 FormulationManufacturingFacility